1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Ganymed Pharmaceuticals AG - Product Pipeline Review - 2015

Ganymed Pharmaceuticals AG - Product Pipeline Review - 2015

  • February 2015
  • -
  • Global Markets Direct
  • -
  • 32 pages

Ganymed Pharmaceuticals AG - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Ganymed Pharmaceuticals AG - Product Pipeline Review - 2015’, provides an overview of the Ganymed Pharmaceuticals AG’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Ganymed Pharmaceuticals AG’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Ganymed Pharmaceuticals AG including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Ganymed Pharmaceuticals AG’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Ganymed Pharmaceuticals AG’s pipeline products

Reasons to buy

- Evaluate Ganymed Pharmaceuticals AG’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Ganymed Pharmaceuticals AG in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Ganymed Pharmaceuticals AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Ganymed Pharmaceuticals AG and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Ganymed Pharmaceuticals AG
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Ganymed Pharmaceuticals AG and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Ganymed Pharmaceuticals AG - Product Pipeline Review - 2015
Table of Contents
Ganymed Pharmaceuticals AG Snapshot 5
Ganymed Pharmaceuticals AG Overview 5
Key Information 5
Key Facts 5
Ganymed Pharmaceuticals AG - Research and Development Overview 6
Key Therapeutic Areas 6
Ganymed Pharmaceuticals AG - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Ganymed Pharmaceuticals AG - Pipeline Products Glance 10
Ganymed Pharmaceuticals AG - Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Phase I Products/Combination Treatment Modalities 11
Ganymed Pharmaceuticals AG - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
Discovery Products/Combination Treatment Modalities 13
Ganymed Pharmaceuticals AG - Drug Profiles 14
IMAB-362 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
IMAB-027 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
GT-352 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
GT-353 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
GT-468 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
Monoclonal Antibodies to Inhibit CDLN18.2 for Solid Tumors 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
Monoclonal Antibodies to Inhibit CLDN6 for Solid Tumor 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
Monoclonal Antibody Conjugates to Inhibit CDLN18.2 for Solid Tumors 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
Monoclonal Antibody Conjugates to Inhibit CLDN6 for Solid Tumors 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
Ganymed Pharmaceuticals AG - Pipeline Analysis 24
Ganymed Pharmaceuticals AG - Pipeline Products by Target 24
Ganymed Pharmaceuticals AG - Pipeline Products by Route of Administration 25
Ganymed Pharmaceuticals AG - Pipeline Products by Molecule Type 26
Ganymed Pharmaceuticals AG - Pipeline Products by Mechanism of Action 27
Ganymed Pharmaceuticals AG - Recent Pipeline Updates 28
Ganymed Pharmaceuticals AG - Locations And Subsidiaries 30
Head Office 30
Appendix 31
Methodology 31
Coverage 31
Secondary Research 31
Primary Research 31
Expert Panel Validation 31
Contact Us 31
Disclaimer 32

List of Tables
Ganymed Pharmaceuticals AG, Key Information 5
Ganymed Pharmaceuticals AG, Key Facts 5
Ganymed Pharmaceuticals AG - Pipeline by Indication, 2015 7
Ganymed Pharmaceuticals AG - Pipeline by Stage of Development, 2015 8
Ganymed Pharmaceuticals AG - Monotherapy Products in Pipeline, 2015 9
Ganymed Pharmaceuticals AG - Phase II, 2015 10
Ganymed Pharmaceuticals AG - Phase I, 2015 11
Ganymed Pharmaceuticals AG - Preclinical, 2015 12
Ganymed Pharmaceuticals AG - Discovery, 2015 13
Ganymed Pharmaceuticals AG - Pipeline by Target, 2015 24
Ganymed Pharmaceuticals AG - Pipeline by Route of Administration, 2015 25
Ganymed Pharmaceuticals AG - Pipeline by Molecule Type, 2015 26
Ganymed Pharmaceuticals AG - Pipeline Products by Mechanism of Action, 2015 27
Ganymed Pharmaceuticals AG - Recent Pipeline Updates, 2015 28

List of Figures
Ganymed Pharmaceuticals AG - Pipeline by Top 10 Indication, 2015 7
Ganymed Pharmaceuticals AG - Pipeline by Stage of Development, 2015 8
Ganymed Pharmaceuticals AG - Monotherapy Products in Pipeline, 2015 9
Ganymed Pharmaceuticals AG - Pipeline by Top 10 Target, 2015 24
Ganymed Pharmaceuticals AG - Pipeline by Top 10 Route of Administration, 2015 25
Ganymed Pharmaceuticals AG - Pipeline by Top 10 Molecule Type, 2015 26
Ganymed Pharmaceuticals AG - Pipeline Products by Top 10 Mechanism of Action, 2015 27

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Pipeline Review, H2 2016

Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Pipeline Review, H2 2016 Summary Global ...

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Review, H2 2016

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.